外源性肺表面活性物质治疗新生儿呼吸窘迫综合征研究进展  

Exogenous Pulmonary Surfactant in Treatment of Infant Respiratory Distress Syndrome

作　　者：宋宏梅 SONG Hongmei(Chengfei Hospital,Sichuan,Chengdu 610091,China)

机构地区：[1]成飞医院,四川成都610091

出　　处：《大医生》2020年第7期127-128,共2页Doctor

摘　　要：呼吸窘迫综合征是新生儿常见的一种并发症,多是由于新生儿肺泡表面活性物质(PS)缺乏,引起肺泡萎陷、呼吸困难、呼吸衰竭等表现,对新生儿的生命安全造成严重威胁。研究发现猪肺PS和牛肺PS等肺表面活性物质替代治疗对新生儿呼吸窘迫综合征有显著的治疗效果。本文对外源性肺表面活性物质治疗新生儿呼吸窘迫综合征研究进展进行综述。Respiratory distress syndrome is a common complication of neonate,which is caused by the lack of pulmonary alveolar surfactant(PS),the collapse of alveoli,dyspnea,respiratory failure and so on Is a serious threat.It was found that the replacement therapy of pulmonary surfactant such as porcine lung PS and bovine lung PS had significant therapeutic effect on neonatal respiratory distress syndrome.This article reviews the research progress of exogenous pulmonary surfactant in the treatment of neonatal respiratory distress syndrome.

关 键 词：外源性肺表面活性物质 新生儿呼吸窘迫综合征 

分 类 号：R72[医药卫生—儿科]